Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 15, 2019 07:00 ET | Source: Optinose, Inc.

Optinose to Highlight Data at the 2019 AAAAI Annual Meeting in San Francisco

YARDLEY, Pa., Feb. 15, 2019 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
February 04, 2019 07:00 ET | Source: Optinose, Inc.

Optinose Announces License Agreement

YARDLEY, Pa., Feb. 04, 2019 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on the development and commercialization of products for patients treated by ear, nose and...
December 11, 2018 07:00 ET | Source: OptiNose, Inc.

Optinose Announces Update to License Agreement with Avanir Pharmaceuticals for ONZETRA XSAIL

YARDLEY, Pa., Dec. 11, 2018 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
December 10, 2018 07:00 ET | Source: OptiNose, Inc.

Optinose Announces First Patient Enrolled in Clinical Trial of XHANCE for Chronic Sinusitis

YARDLEY, Pa., Dec. 10, 2018 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, announced today...
December 05, 2018 16:30 ET | Source: OptiNose, Inc.

Optinose to Present at the BMO Capital Markets Prescriptions for Success Healthcare Conference

YARDLEY, Pa., Dec. 05, 2018 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
November 13, 2018 07:00 ET | Source: OptiNose, Inc.

Optinose Reports Third Quarter 2018 Financial Results and Recent Operational Highlights

Company reports third quarter net XHANCE revenue of $1.9 million Company reports 42% monthly XHANCE prescription growth from August to October Conference call and webcast to be held today at 8:00...
October 31, 2018 16:30 ET | Source: OptiNose, Inc.

Optinose to Report Third Quarter 2018 Financial Results and Corporate Updates on November 13, 2018

Conference Call and Webcast Scheduled for Tuesday, November 13 at 8:00 a.m. Eastern Time YARDLEY, Pa., Oct. 31, 2018 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on...
October 03, 2018 07:00 ET | Source: OptiNose, Inc.

Optinose to Highlight Data at Two Upcoming Scientific Meetings

YARDLEY, Pa., Oct. 03, 2018 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
September 24, 2018 16:30 ET | Source: OptiNose, Inc.

Optinose to Present at the 2018 Cantor Global Healthcare Conference

YARDLEY, Pa., Sept. 24, 2018 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
August 14, 2018 07:00 ET | Source: OptiNose, Inc.

Optinose Reports Second Quarter 2018 Financial Results and Recent Operational Highlights

Company reports second quarter net product sales of $1.3 million and that more than 2,600 physicians have prescribed XHANCE since launch Conference call and webcast to be held today at 8:00 a.m....